Biological response modifiers in renal cancer.
Ackermann
R
R
Department of Urology, University of Düsseldorf, Federal Republic of Germany.
D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D007694:Killer Cells, Natural / Q000276:immunology; D008222:Lymphokines / Q000276:immunology; D013947:Thymosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D007376:Interleukin-2; D008222:Lymphokines; D014409:Tumor Necrosis Factor-alpha; C033782:thymosin fraction 5; D013947:Thymosin; D007372:Interferons